BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SAR447971 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SAR447971\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07629336-11337@assetmemo.bio
DTSTAMP:20261121T005556Z
DTSTART;VALUE=DATE:20280417
DTEND;VALUE=DATE:20280418
SUMMARY:SAR447971: Phase 1 readout est. (NCT07629336)
DESCRIPTION:SAR447971\, phase 1.\nStudy: SAR447971 First-in-human Study\nEs
 timated primary completion: 17 April 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/sar447971#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07629336
URL:https://assetmemo.bio/drug/sar447971#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
